ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 5

Safety Considerations for PV Therapy

, , , ,

Panelists discuss the safety profiles of therapies for polycythemia vera (PV) and the safety considerations they take into account when determining which patients are best suited for these treatments.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Initial Treatment Strategies for Polycythemia Vera
    EP. 2: Cytoreductive Therapy in PV Treatment Paradigm
    EP. 3: JAK Inhibition in Polycythemia Vera: Treatment Updates
    EP. 4: Interferon Therapy in PV
    Now Viewing
    EP. 5: Safety Considerations for PV Therapy
    EP. 6: Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence
    EP. 7: Interferon Real- World Treatment Patterns in PV
    EP. 8: Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
    EP. 9: Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024
    EP. 10: An Overview to Myelofibrosis and Disease Risk
    EP. 11: Treatment Goals for Myelofibrosis
    EP. 12: Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials
    EP. 13: Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib
    EP. 14: Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice
    EP. 15: Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches
    EP. 16: Myelofibrosis at ASH 2024: Key Updates and Emerging Therapies
    EP. 17: MPN Milestones of 2024 and What’s Next for 2025

    Video content above is prompted by the following:

    • What are your thoughts on the safety profiles of these therapies for PV?
    • What safety considerations do you weigh when determining which patients are best suited for these therapies?
    x